Skip to main content
. 2023 Jan 22;28(3):1104. doi: 10.3390/molecules28031104

Figure 3.

Figure 3

SARS-CoV-2 main protease (3CLpro) inhibition of α-mangostin (1) and N-containing α-mangostin analogs (24). (A) Relative protease activities treated with 100 μM of compounds 14 and rutin (positive control). (B) Activity of 3CLpro at various inhibitor concentrations.